Actively Recruiting
Randomized, Double-Blind, Placebo-Controlled Phase II Trial Evaluating RC1416 Injection for Adults with Moderate to Severe Asthma
Led by Nanjing RegeneCore Biotech Co., Ltd. · Updated on 2026-09-10
195
Participants Needed
44
Research Sites
18 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating RC1416, a bispecific homodimer nanobody, in adults with severe uncontrolled asthma to assess its effectiveness and safety. This phase II study involves 195 participants diagnosed with moderate to severe asthma, aiming to improve lung function and reduce asthma symptoms according to the 2024 GINA guidelines. Participants will be randomly assigned to receive either RC1416 or a placebo by subcutaneous injection. Two different doses of RC1416 will be tested. The study will last 32 weeks, during which participants will be monitored regularly for treatment effects and safety. Throughout the study, participants will undergo lung function tests such as pre-bronchodilator forced expiratory volume in 1 second FEV1, peak expiratory flow, and forced vital capacity measurements. They will also complete questionnaires about asthma control and quality of life. Researchers will track asthma exacerbations, medication use, and adverse events. Blood samples will be collected for pharmacokinetics, pharmacodynamics, and anti-drug antibody analysis, ensuring comprehensive safety and efficacy monitoring for up to 32 weeks.
CONDITIONS
Brief Title
Phase II Trial of RC1416 Injection in Asthma
Research Team
G
Guo Qian
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here